长效干扰素治疗慢性丙型肝炎临床分析

Clinical Analysis of Long-acting Interferon for Chronic Hepatitis C

目的探讨长效干扰素治疗慢性丙型肝炎的临床疗效和安全性,为慢性丙乙肝的临床诊治提供数据支持。方法回顾性分析2008年3月至2010年3月我院采用长效干扰素联合胸腺肽进行治疗的慢性丙型乙肝患者的临床资料,并以采用干扰素联合病毒唑治疗的患者为对照组,对两组患者治疗效果和相关不良反应的发生情况进行比较。结果观察组治疗结束时应答112例,对照组108例,观察组治疗组治疗效果由于对照组,但是组间比较差异无统计学意义(P>0.05)。结论长效干扰素治疗慢性丙型肝炎临床疗效确切,可作为临床治疗慢性丙型肝炎的首选药物。

Objective To investigate the long-acting interferon for chronic hepatitis C clinical efficacy and safety for the clinical diagnosis and treatment of chronic hepatitis C to provide data support.Methods Retrospective analysis of March 2008～March 2010 in our hospital with long-acting interferon and thymosin treatment of chronic hepatitis C clinical data of patients with hepatitis B,and interferon combined with ribavirin with patients treated control group,two groups of patients and treatment-related adverse reactions were compared.Results Observed when the end of treatment response group and 112 patients in control group 108 patients,group treatment,the observed effect of the control group,but differences between groups was not significant（P0.05）.Conclusion The long-acting interferon for chronic hepatitis C clinical efficacy,can be used as clinical treatment of chronic hepatitis C drug of choice.